All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 324.80 points (-1.9%) at 16,666 as of Friday, Aug. 21, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 525 issues advancing vs. 2,498 declining with 133 unchanged.

The Diversified Services industry as a whole closed the day down 1.5% versus the S&P 500, which was down 1.7%. Top gainers within the Diversified Services industry included Kelly Services ( KELYB), up 3.9%, SmartPros ( SPRO), up 5.1%, ATRM Holdings ( ATRM), up 4.2%, Bioanalytical Systems ( BASI), up 2.3% and AeroCentury ( ACY), up 2.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

AeroCentury ( ACY) is one of the companies that pushed the Diversified Services industry higher today. AeroCentury was up $0.22 (2.5%) to $8.99 on heavy volume. Throughout the day, 4,956 shares of AeroCentury exchanged hands as compared to its average daily volume of 2,200 shares. The stock ranged in a price between $8.44-$9.14 after having opened the day at $8.45 as compared to the previous trading day's close of $8.77.

AeroCentury Corp., an aircraft operating lessor and finance company, acquires and invests in used regional aircraft and aircraft engines for lease to regional airlines and commercial users worldwide. AeroCentury has a market cap of $13.9 million and is part of the services sector. Shares are up 0.7% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates AeroCentury a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates AeroCentury as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ACY go as follows:

  • The debt-to-equity ratio is very high at 3.54 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Trading Companies & Distributors industry and the overall market, AEROCENTURY CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to $2.96 million or 38.05% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • ACY's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 40.16%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • ACY, with its decline in revenue, underperformed when compared the industry average of 2.6%. Since the same quarter one year prior, revenues fell by 10.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.

You can view the full analysis from the report here: AeroCentury Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Bioanalytical Systems ( BASI) was up $0.03 (2.3%) to $1.35 on average volume. Throughout the day, 13,180 shares of Bioanalytical Systems exchanged hands as compared to its average daily volume of 14,000 shares. The stock ranged in a price between $1.27-$1.44 after having opened the day at $1.27 as compared to the previous trading day's close of $1.32.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems has a market cap of $11.9 million and is part of the services sector. Shares are down 39.4% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Bioanalytical Systems a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Bioanalytical Systems as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on BASI go as follows:

  • BASI's revenue growth has slightly outpaced the industry average of 5.6%. Since the same quarter one year prior, revenues slightly increased by 2.0%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The current debt-to-equity ratio, 0.44, is low and is below the industry average, implying that there has been successful management of debt levels. Despite the fact that BASI's debt-to-equity ratio is low, the quick ratio, which is currently 0.58, displays a potential problem in covering short-term cash needs.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. When compared to other companies in the Life Sciences Tools & Services industry and the overall market, BIOANALYTICAL SYSTEMS INC's return on equity is below that of both the industry average and the S&P 500.
  • BASI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 28.88%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: Bioanalytical Systems Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ATRM Holdings ( ATRM) was another company that pushed the Diversified Services industry higher today. ATRM Holdings was up $0.12 (4.2%) to $2.99 on light volume. Throughout the day, 1,000 shares of ATRM Holdings exchanged hands as compared to its average daily volume of 6,400 shares. The stock ranged in a price between $2.89-$2.99 after having opened the day at $2.89 as compared to the previous trading day's close of $2.87.

ATRM Holdings, Inc., through its subsidiary, KBS Builders, Inc., manufactures, sells, and distributes modular buildings for commercial and residential applications in the New England states. ATRM Holdings has a market cap of $3.4 million and is part of the services sector. Shares are down 1.4% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate ATRM Holdings a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ATRM Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ATRM go as follows:

  • ATRM HOLDINGS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, ATRM HOLDINGS INC reported poor results of -$8.33 versus -$1.99 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income has significantly decreased by 657.6% when compared to the same quarter one year ago, falling from -$0.20 million to -$1.49 million.
  • Net operating cash flow has significantly decreased to -$3.02 million or 575.74% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 49.12%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 160.41% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: ATRM Holdings Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.